OralParenteralDosed ingredient Cosmetic cross-reference

Ascorbic Acid

CAS 50-81-7

Ascorbic Acid (CAS 50-81-7) is a Phase 4 pharmaceutical compound with 7 bioactivity targets and 7,867 adverse event associations.

SOURCE NLM DailyMed

Label records

SOURCE EMBL-EBI ChEMBL

Bioactivity

SOURCE DrugCentral

Adverse signals

7,867

SOURCE IUPHAR/BPS

PubMed IDs

SOURCE EMBL-EBI ChEMBL B25820EEF0F0

Compound Identity

Matched identifiers and naming fields for the pharmaceutical compound record.

Primary Name

Ascorbic Acid

CAS Number

50-81-7

UNII

PQ6CK8PD0R

InChIKey

CIWBSHSKHKDKBQ-JLAZNSOCSA-N

ChEMBL ID

CHEMBL196

Molecule Type

Small molecule

Source Match

EMBL-EBI ChEMBL (INCHIKEY)

dosed ingredientnatural productoralparenteral

SOURCE EMBL-EBI ChEMBL B25820EEF0F0

Clinical Development Phase

Highest clinical development phase rendered from the matched compound identifier rows.

Phase 4 (Approved)

Approved or marketed human pharmaceutical use is represented in the source phase field.

ChEMBL CHEMBL196 | Small molecule

SOURCE Ingredients table / CosIng profile same-CAS cross-reference

Cross-Reference to Cosmetics

Same-CAS ingredient record found in the cosmetics vertical.

This substance also has a cosmetic safety profile →

SOURCE EMBL-EBI ChEMBL 15 bioactivity rows

Bioactivity & Target Interactions

Target-level activity records with assay counts, activity type, and measured value where present.

Target	Activity	Value	Assays	Organism
-	IC50	31017.225674157304 nM	177	-
-	IC50	17.51586813186813 ug.mL-1	91	-
-	AC50	27051.717647058824 nM	34	-
-	EC50	19976.690476190477 nM	21	-
-	EC50	11.9735 ug.mL-1	20	-
-	MIC	3.5033333333333334 ug	3	-
-	IC50	4.2 10^-5 uM	1	-
-	Ki	43400 nM	1	-
Urease Enzyme	IC50	5.07	-	Canavalia ensiformis
Pancreatic alpha-amylase Enzyme	IC50	4.58	-	Rattus norvegicus
Tyrosinase Enzyme	IC50	4.49	-	Homo sapiens
Prolyl 4-hydroxylase subunit alpha-1 Enzyme	-	-	-	Homo sapiens
Procollagen-lysine,2-oxoglutarate 5-dioxygenase 1 Enzyme	-	-	-	Homo sapiens
Solute carrier family 23 member 2 Transporter	-	-	-	Homo sapiens
Solute carrier family 23 member 1 Transporter	-	-	-	Homo sapiens

SOURCE DrugCentral 80 associations

Adverse Event Associations

DrugCentral / FAERS disproportionality signal rows matched to this compound.

Reaction PT	Drug AE	LLR	MedDRA
Pemphigus	5420	1993.897	10034280
Systemic lupus erythematosus	5763	1898.796	10042945
Glossodynia	5005	1675.724	10018388
Toxicity to various agents	1216	1674.897	10070863
Completed suicide	195	1638.136	10010144
Rheumatoid arthritis	6398	1463.196	10039073
Hand deformity	4359	1390.134	10061194
Arthropathy	5830	1358.616	10003285
Alopecia	7187	1289.809	10001760
Abdominal discomfort	7401	1286.828	10000059
Pain	14344	1196.571	10033371
Wound	4259	1124.643	10052428
Joint swelling	7212	1123.351	10023232
Drug interaction	1731	1088.785	10013710
Maternal exposure during pregnancy	4811	1036.153	10071408
Drug abuse	211	977.615	10013654
Contraindicated product administered	5023	909.936	10078504
Synovitis	4300	904.141	10042868
Swelling	5857	880.485	10042674
Death	4393	861.529	10011906
Anti-cyclic citrullinated peptide antibody positive	2953	840.932	10068798
Infusion related reaction	5781	827.266	10051792
Discomfort	3953	822.027	10013082
Pericarditis	3279	777.813	10034484
Intentional overdose	146	715.213	10022523
Arthralgia	10839	703.586	10003239
Acute kidney injury	3117	640.29	10069339
Febrile neutropenia	1038	589.486	10016288
Hepatic enzyme increased	4300	564.795	10060795
Psoriatic arthropathy	2379	541.24	10037162
Duodenal ulcer perforation	2104	517.733	10013849
Helicobacter infection	2190	505.138	10054263
Rheumatoid factor positive	1974	491.32	10039080
Suicide attempt	185	474.727	10042464
Exposure during pregnancy	3120	449.993	10073513
Nasopharyngitis	5092	448.644	10028810
Musculoskeletal stiffness	3896	446.646	10052904
Fatigue	15714	432.278	10016256
Overdose	934	431.301	10033295
Product use issue	4718	416.612	10076309
Therapeutic product effect decreased	3781	376.508	10082201
Cardiac arrest	783	363.131	10007515
Drug intolerance	5529	354.588	10061822
Sinusitis	4063	343.985	10040753
Disease progression	1227	343.324	10061818
Neutropenia	2010	339.712	10029354
Drug reaction with eosinophilia and systemic symptoms	116	333.412	10073508
Cardiac failure	789	326.912	10007554
Rhabdomyolysis	353	324.092	10039020
Hypersensitivity	5183	313.317	10020751

Association rows are source-linked signal records, not incidence rates or clinical causality claims.

SOURCE NLM RxNorm 5 name rows

Drug Names / RxNorm

Normalized drug-name vocabulary rows, RxCUIs, and source abbreviations.

Name	RxCUI	Type	Source
Ascorbic Acid	1151	SU	MTHSPL
ascorbic acid	1151	SU	MTHSPL
ASCORBIC ACID	1151	SU	MTHSPL
Ascorbic acid	1151	SU	MTHSPL
ascorbic acid	1151	IN	RXNORM

SOURCE Rendered pharma page rows FAQPage JSON-LD

Frequently Asked Questions

Short answers generated only from the same visible source-linked rows on this page.

What is Ascorbic Acid used for in pharmaceutical contexts?

Ascorbic Acid (CAS 50-81-7) is rendered as a pharmaceutical compound from the matched source rows; no DailyMed product-name rows are present in this page query.

What are the known adverse events for Ascorbic Acid?

Ascorbic Acid has 7,867 DrugCentral/FAERS adverse event associations. Rendered reaction terms include Pemphigus, Systemic lupus erythematosus, Glossodynia, Toxicity to various agents, Completed suicide. Signal rows are source-linked records and should not be read as incidence rates or causality conclusions.

Is Ascorbic Acid also used in cosmetics?

Yes. The ingredients table has a same-CAS cosmetic profile for Ascorbic Acid with EU status "permitted".

What clinical phase is Ascorbic Acid in?

Ascorbic Acid is rendered with ChEMBL max phase 4 (approved).

What bioactivity targets are documented for Ascorbic Acid?

Ascorbic Acid has 15 bioactivity rows in this page query. Rendered target entries include Urease, Pancreatic alpha-amylase, Tyrosinase, Prolyl 4-hydroxylase subunit alpha-1, Procollagen-lysine,2-oxoglutarate 5-dioxygenase 1.